Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05611931 · ClinicalTrials.gov registry record · Phase 3
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
A Phase 3 study of Endometrial Cancer, sponsored by Karyopharm Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 276
- Enrollment target
- 20
- Study locations
NCT05611931 is a Phase 3 study of Endometrial Cancer that is actively recruiting participants, run by Karyopharm Therapeutics. The registered enrollment target is 276 participants, below the 523-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (47% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT05611931, a Phase 3 study of Endometrial Cancer, is actively recruiting participants, sponsored by Karyopharm Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 276 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v 1.1\]) after completing at least 12 weeks of platinum-based therapy. A total of 276 participants will be enrolled in the study and randomized in a 1:1 ratio to maintenance therapy with either selinexor or placebo.
Conditions Studied
Interventions
- DRUG Selinexor
- DRUG Matching Placebo for selinexor
Study Locations (20)
California
- UC DAVIS - Davis
- City of Hope National Medical Center - Duarte
- Chao Family Comprehensive Cancer Center and Ambulatory Care - Irvine
- City of Hope at Irvine Lennar - Irvine
- Cancer and Blood Specialty Clinic - Los Alamitos
- UCLA - Women's Health Clinical Research Unit - Los Angeles
- Long Beach Memorial Medical Center - Los Angeles
- UC Irvine - Orange
- Stanford University - Palo Alto
- California Pacific Medical Center - San Francisco
Florida
- Broward Health Medical Center - Fort Lauderdale
- Mount Sinai Comprehensive Cancer Center - Miami Beach
- Advent Health - Orlando
Colorado
- Highlands Ranch Hospital - Highlands Ranch
- University of Colorado Cancer Center - Highlands Ranch
Georgia
- Grady Hospital - Atlanta
- Emory University - Atlanta
Alabama
- The University of Alabama at Birmingham - Birmingham
Arizona
- Honor Health - Phoenix
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 276 participants |
| Start Date | 2023-04-18 |
| Est. Completion | 2028-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05611931
The ClinicalTrials.gov registry entry for NCT05611931 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 276 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 523-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (47% lower). The listed sponsor is Karyopharm Therapeutics, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 2 interventions - of which Selinexor is the first listed.
NCT05611931 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT05611931 about?
NCT05611931 is a clinical study titled "Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma". The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v 1....
What is the current status of trial NCT05611931?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 276 participants. The study started on 2023-04-18. Estimated completion is 2028-01.
What conditions does trial NCT05611931 study?
This clinical trial studies the following conditions: Endometrial Cancer.
What interventions are being tested in trial NCT05611931?
The interventions under investigation include: Selinexor (DRUG), Matching Placebo for selinexor (DRUG).
Who is sponsoring clinical trial NCT05611931?
This trial is sponsored by Karyopharm Therapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05611931 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
RECRUITING · Phase 3
-
Vaginal Cuff Brachytherapy Fractionation Study
RECRUITING · Phase 3
-
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
RECRUITING · Phase 3
-
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
RECRUITING · Phase 3
-
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
RECRUITING · Phase 3
-
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.